Meeting
2020 Genitourinary Cancers Symposium
A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer.
Authors
David R. Wise
New York University Medical Center, New York, NY
David R. Wise , Olivia Gardner , Houston N. Gilbert , Aimee Rieger , Melissa Constance Paoloni , Kartik Krishnan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS272)
Abstract #
TPS272
Poster Bd #
P16
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2021 Genitourinary Cancers Symposium
Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.
First Author: Adam Kessel
Poster
2021 Genitourinary Cancers Symposium
Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Mallika Marar
Poster
2020 Genitourinary Cancers Symposium
Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1).
First Author: Antonin Broyelle